Senior Director, HEOR and Payer Marketing
Who We Are:
Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's.
The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibitor designed to potently target KIT D816V and other mutations in KIT exon 17. These mutations are known drivers of systemic mastocytosis (SM) and advanced gastrointestinal stromal tumors (GIST) - both serious conditions driven by oncogenic KIT signaling. Bezuclastinib is currently being evaluated in multiple registration-directed trials across Non-Advanced SM (NonAdvSM), Advanced SM (AdvSM), and GIST. In July 2025, Cogent announced that its registration-direct SUMMIT trial in patients with NonAdvSM achieved statistical significance across all primary and key secondary endpoints, and the company is on track to file its first New Drug Application for this patient population by the end of 2025. The company also remains on track to announce top-line results for its APEX trial in patients with AdvSM in the second half of 2025 and for its PEAK trial in patients with GIST by the end of 2025. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor, and the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting other serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS.
Through its commitment to precision medicine and targeted innovation, Cogent Biosciences is working to transform the treatment landscape for patients with serious and underserved diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease. Our culture of inquisitiveness fuels continuous learning and innovation; we challenge assumptions, ask bold questions, and embrace a mindset of discovery to uncover transformative insights.
The Role:
The Senior Director, HEOR and Payer Marketing reports to the VP Value and Access Strategy and will lead the development of strategic, evidence-based payer value communication tools that support access for Cogent therapies. This role translates complex clinical, economic, and real-world evidence into compelling value propositions for U.S. payers and key accounts while ensuring alignment with brand positioning and field execution strategies. This role will work cross-functionally with Pricing, Marketing, HEOR, Medical, and Payer/Key Account Director teams to ensure value messages are consistent, credible, and responsive to evolving market access landscape. This position will be based in Waltham, Massachusetts.
Value Communication Strategy & Execution
-
- Partner with Payer and Key Account teams to develop value messages for payer and HCP audiences
- Drive payer coverage, and pull-through across Commercial, Medicare, and Medicaid markets
- Lead HEOR initiatives to develop foundation for the bezuclastinib value messaging platform in collaboration with Medical
- Lead the development of payer and key account value stories and other messaging resources supported by clinical evidence and health economics data to demonstrate the differentiated value of Cogent’s therapies
- Integrate brand strategy into payer messaging by partnering closely with Marketing to ensure alignment across patient, HCP, and payer communication channels
- Anticipate access barriers and articulate clear justifications for formulary inclusion
- Collaborate with Medical to ensure alignment of payer messaging with evidence generation and scientific narratives
- Work with the commercial team to embed access and affordability messaging into HCP engagement plans and marketing tactics
Field Resources and Training
-
- Creation of payer/HCP value prop for use by payer and key account teams
- Create engagement materials for field teams, including objection handlers, and FAQs
- Develop and lead training initiatives to ensure field teams are confident in communicating the clinical and economic value of Cogent’s therapies
Qualifications:
Basic Qualifications
-
- 12+ years of pharmaceutical or biotech experience in market access, pricing, policy, and/or relevant commercial roles
- Demonstrated ability to collaborate cross-functionally and influence decision making, strategy, and execution across partners and functions
- Deep understanding of the access landscape for pharmaceutical benefit products
- Extensive understanding of private and public payers, across all settings of care, including the complexities in each setting
Preferred Qualifications
-
- New product launch and/or start-up experience
- Prior experience in targeted therapies and/or Oncology
- Strong financial management and business acumen
- Track record of developing impactful payer materials in support of field execution
- Background in conducting HEOR analyses and translating HEOR data into a value story
Salary Range:
250,000 - 300,000 $USD
Apply for this job
*
indicates a required field